GSK269962A

CAS No. 850664-21-0

GSK269962A( GSK 269962 )

Catalog No. M17614 CAS No. 850664-21-0

GSK269962 is a selective ROCK(Rho-associated protein kinase) inhibitor with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 47 In Stock
5MG 74 In Stock
10MG 138 In Stock
25MG 291 In Stock
50MG 431 In Stock
100MG 619 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    GSK269962A
  • Note
    Research use only, not for human use.
  • Brief Description
    GSK269962 is a selective ROCK(Rho-associated protein kinase) inhibitor with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively.
  • Description
    GSK269962 is a selective ROCK(Rho-associated protein kinase) inhibitor with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively.
  • In Vitro
    ——
  • In Vivo
    Animal Model:Male Sprague-Dawley rats (350-400g)Dosage:0.3, 1, and 3 mg/kg Administration:Oral gavage; 12 hours Result:Induced a dose-dependent reduction in blood pressure.
  • Synonyms
    GSK 269962
  • Pathway
    Angiogenesis
  • Target
    VEGFR
  • Recptor
    MSK1| ROCK1| ROCK2| RSK1
  • Research Area
    Cardiovascular Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    850664-21-0
  • Formula Weight
    570.61
  • Molecular Formula
    C29H30N8O5
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 30 mg/mL; 52.58 mM
  • SMILES
    CCn1c2cc(ncc2nc1c1nonc1N)Oc1cccc(c1)NC(=O)c1ccc(cc1)OCCN1CCOCC1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Doe C, et al. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98. Epub 2006 Oct 3.
molnova catalog
related products
  • GW297361

    GW297361 is a potent inhibitor of the cell cycle protein-dependent kinase Cdk1 and also inhibits the Pho85 signaling pathway.The IC50s of GW297361 on yeast Cdk1 and Pho85 were 20 nM and 400 nM, respectively.

  • Anemoside A3

    Anemoside A3 is an attractive candidate for further development as a cognitive enhancer capable of alleviating memory dysfunctions associated with aging and neurodegenerative diseases.

  • (E)-FeCP-oxindole

    (E)-FeCP-oxindole is an inhibitor of VEGFR2 with IC50 of 214 nM.